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To the Editor 
Background 
Numerous studies introduced epidermal keratinocytes as “non-classical” immune-
competent cells, hence potent primary regulators and active participants of cutaneous 
immune functions (1, s1-6). Therefore, targeting them might provide a novel, highly 
specific anti-inflammatory therapeutic possibility. The endocannabinoid system (ECS) is 
an emerging signaling network which regulates multiple cutaneous functions (2,3). The 
loss of homeostatic endocannabinoid (eCB) signaling of epidermal keratinocytes was 
shown to dramatically enhance inflammatory processes, arguing for that the cutaneous 
eCB tone plays a “gate-keeper” role in the initiation phase of skin inflammation (4; for 
further details see Supplementary Background section). Moreover, elevation of the 
eCB tone, e.g. by the inhibition of fatty acid amide hydrolase (FAAH), the most important 
enzyme engaged with the degradation of the eCB anandamide (AEA; 5), exerts ECS-
mediated anti-inflammatory actions in multiple organs (5). 
 
Questions addressed 
Based on these data we hypothesized that up-regulation of expression/activity of FAAH 
(thereby decreasing the eCB tone, and increasing the level of the pro-inflammatory “eCB 
degradation product” arachidonic acid [AA]) might contribute to the development of the 
inflammatory processes. Therefore, we aimed at investigating (i) mRNA and protein 
expressions and activity of FAAH in human keratinocytes in Toll-like receptor (TLR)-
induced inflammation models; and (ii) the suggested anti-inflammatory effects of two 
newly developed, potent and selective N-alkylcarbamate FAAH-inhibitors WOBE440 
(IC50=25±8 nM) and WOBE479 (IC50=78±13 nM) (Supplementary Figure S1) which 
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show high specificity over other known targets within the ECS (IC50>10 µM for 
cannabinoid receptor [CNR]-1, CNR2, monoacylglycerol lipase and the putative 
endocannabinoid membrane transporter) (6) on primary (NHEK) and immortalized 
(HPV-KER; 7,8) human epidermal keratinocytes as well as in NC/Tnd mice, a widely 
used animal model of atopic dermatitis (AD; 9). 
 
Experimental design 
Detailed description of the methods can be found in the Supplementary Experimental 
design section. 
Cell culture 
Human skin samples were obtained after obtaining written informed consent from 
healthy individuals, adhering to Helsinki guidelines, and after obtaining permissions from 
respective institutional and government bodies (protocol No.: DE OEC RKEB/IKEB 
3724-2012; document No.: IX-R-052/01396-2/2012). 
 
Determination of cellular viability, apoptosis and necrosis 
Viability and cell death were determined by MTT and DilC1(5)-SYTOX Green assays as 
described previously (s11). 
 
Expression analysis 
Molecular expression was monitored by Q-PCR and Western blot as described 
previously with slight modifications (s11). The released amount of IL6 and IL8 was 
Page 3 of 40
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
4 
 
determined using OptEIA kits (BD Pharmingen, Franklin Lakes, NJ, USA) according to 
the manufacturer’s protocol. 
 
Determination of the FAAH-activity 
The enzymatic activity of FAAH in NHEKs and HPV-KERs homogenates was assessed 
by determination of the hydrolysis of [ethanolamine-1-3H]AEA as previously described 
(s12-16). 
 
Experiments on NC/Tnd mice 
The study was conducted at BioTox Sciences (BTS; San Diego, CA, USA). The study 
design and animal usage were reviewed and approved by the Institutional Animal Care 
and Use Committee (IACUC; No. 1109-05). Clinical score was determined from 
observations of the upper back/lower neck with a scale of 0–3 (0: absent; 1: mild; 2: 
moderate; 3: severe) for erythema, edema or papulations, and for oozing, crusts or 
hemorrhages. Each mouse received a single daily topical dose that was applied to the 
upper back/lower neck area. 
 
Statistical analysis 
Data were analyzed and graphs were plotted by using Origin Pro Plus 6.0 software 
(Microcal, Northampton, MA, USA), using Student’s two-tailed two samples t-test and 
P<0.05 values were regarded as significant differences. 
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Results 
We found that FAAH is expressed in HPV-KERs both at the mRNA and protein levels 
(Supplementary Figure S2; Figure 1a-b). Importantly, we also found that upon 
administration of TLR2 or -4-activators (lipoteichoic acid [LTA] and lipopolysaccharide 
[LPS], respectively), expression of FAAH at the protein level tended to be increased. 
Interestingly, at the mRNA level, only 3-hr LPS treatment induced significant increase 
(Figure 1a-b; Supplementary Figure S2), and in NHEKs, only LTA was able to 
enhance the expressi n (Figure 1c-d). Importantly, both HPV-KERs and NHEKs 
exhibited significant elevations in FAAH-activity upon TLR2-activation (Figure 1e-f). The 
above findings raised the possibility that the decreased eCB mediated by FAAH up-
regulation might theoretically contribute to the development of the TLR-activation-
induced pro-inflammatory responses in the human skin. To challenge this hypothesis, 
next, we investigated the putative anti-inflammatory effects of selective FAAH-inhibitors, 
by monitoring the production of key pro-inflammatory cytokines (IL1A, IL1B, IL6 and IL8; 
s17-19). As expected, both the commercially available FAAH-inhibitor URB597 (s20), as 
well as novel inhibitors (WOBE440 and WOBE479) almost completely prevented the 
LTA-induced up-regulation of the aforementioned cytokines (Figure 2a-b). Importantly, 
they also significantly suppressed the LTA-induced release of IL6 and IL8 (Figure 2c-d). 
FAAH-inhibitors exert their effects via the elevation of the local AEA tone, which 
subsequently activates CNR1 and CNR2 (5). In a good agreement with the literature 
data (4), combined antagonism of these receptors markedly abolished the anti-
inflammatory actions of the FAAH-inhibitors (Supplementary Figure S3). Importantly, 
concentrations of FAAH-inhibitors having been proven to exert anti-inflammatory actions 
(i.e. 100 and 200 nM for WOBE440 and WOBE479, respectively) did not induce any 
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measurable cytotoxicity when applied either in short-term (8- and 24-hr; Supplementary 
Figure S4a-d), or in long-term experiments (72-hr; Supplementary Figure S5a-b), 
indicating that they can most probably be administered without the risk of significant 
cutaneous cytotoxicity. Finally, we aimed at investigating the putative in vivo efficiency of 
the FAAH-inhibitors, employing a widely accepted animal model of AD, i.e. the NC/Tnd 
mice (9). After appropriate antigen exposure and the development of AD-like cutaneous 
symptoms, mice were treated with the novel FAAH-inhibitors or vehicle, as described in 
the Supplementary Experimental Design section. As a “positive” control, tacrolimus 
ointment (Protopic®; commonly administered in the treatment of AD; s21) was used. Of 
great importance, FAAH-inhibitors significantly reduced both the total disease score (for 
details, see Supplementary Experimental design section) and ear thickness. It is also 
important to note that beneficial effects of the FAAH-inhibitors were comparable to those 
exerted by tacrolimus (Figure 2e-f; Supplementary Figure S6a-d), and that no 
(obvious macroscopic or behavioral) side-effects developed during the one month-long 
drug administration. These data strongly suggest that inhibition of FAAH results in 
substantial anti-inflammatory actions in vivo as well. 
 
Conclusions 
For detailed discussion, see Supplementary Conclusion section 1. Taken together, 
our results introduce FAAH as an important, TLR2-dependent regulator of cutaneous 
inflammatory processes (Supplementary Figure S7a-b). Thus, according to our 
translationally relevant, complementary in vitro and in vivo data, local inhibition of FAAH 
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could provide a highly targeted and hence most probably side-effect-free tool for 
mitigating cutaneous inflammation (further discussion of the expected beneficial effects 
can be found in the Supplementary Conclusion section 2). Therefore, these data 
should encourage one to test, next in appropriate clinical trials the in vivo efficiency of 
the FAAH-inhibitors in the management of inflammatory skin diseases, such as e.g. AD. 
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FIGURE LEGENDS 
Figure 1 Protein expression and activity of FAAH is up-regulated upon Toll-like receptor 
activation in immortalized (HPV-KER) and primary (NHEK) human epidermal 
keratinocytes 
(a-d) Western blot analysis of lysates of HPV-KERs (a) or NHEKs (c) treated with LPS, 
LTA (5 and 10 µg/ml, respectively) or vehicle (24 hrs). Two additional experiments 
yielded similar results. (b, d) Statistical analyses of the above Western blot experiments 
(c: HPV-KER; d: NHEK). OD: optical density of the FAAH bands normalized to the 
corresponding β-tubulin (TUBB) signals. Data are presented as mean±SEM of 3 
independent experiments regarding vehicle control as 1 (solid line). *P<0.05 vs. control 
group. (e-f) Measurement of FAAH-activity on HPV-KERs (c) and on NHEKs (d) 
following 24-hr treatments with LTA (10 µg/ml) or vehicle. Specific inhibition of FAAH 
activity ([3H]AEA hydrolysis) was achieved with URB597 (100 nM). Data are expressed 
as mean±SEM of three independent experiments each of them performed in triplicates. 
**, *** P<0.01 and 0.001, respectively; n.s.: non-significant difference. 
 
Figure 2 FAAH-inhibitors exert significant anti-inflammatory actions both in vitro and in 
vivo 
(a-b) Q-PCR analyses of HPV-KERs following the indicated 24-hr treatments (LTA: 10 
µg/ml; URB597: 100 nM; WOBE440: 100 nM; WOBE479: 200 nM). Data are presented 
by using ∆∆CT method regarding PPIA-normalized mRNA expressions of the vehicle 
control as 1 (solid line). Data are expressed as mean±SD of 3 independent 
determinations. Two additional experiments yielded similar results. (c-d) Determination 
of the released cytokine concentration following 24-hr treatments (LTA: 10 µg/ml; 
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WOBE440: 100 nM; WOBE479: 200 nM). Data are presented as mean±SEM of three 
independent determinations. One additional experiment yielded similar results. (a-d) 
*P<0.05 compared to the vehicle control. #P<0.05 compared the LTA-treated, FAAH-
inhibitor-free group. (e-f) Alterations in total ear thickness (e) and in total disease score 
(f) following the indicated treatments (tacrolimus: 0.1 [w/v]%; WOBE440 and -479: 1 
[w/v]%). *, ** and *** mark significant (P<0.05, 0.01 or 0.001, respectively) differences of 
the graphs with the same color compared to the daily control group. N=8-9 animals were 
investigated in each group. 
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Supporting Information 
Additional data (Supplementary Background, Supplementary Experimental Design, 
Supplementary Conclusion sections 1-2, Supplementary Figures S1-7, 
Supplementary References s1-s29) can be found in the Supporting Information. 
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Figure 1 ± Protein expression and 
activity of FAAH is up-regulated upon 
Toll-like receptor activation in human 
keratinocytes 
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Figure 2 – FAAH-inhibitors exert 
remarkable anti-inflammatory actions 
both in vitro and in vivo 
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SUPPLEMENTARY MATERIAL 
 
Supplementary Background 
The endocannabinoid system (ECS) is an emerging signaling network, which regulates 
multiple cutaneous functions (see reviewed in 2). Notably, by using mice lacking both 
CNR1 and CNR2 cannabinoid receptors, Karsak et al. have elegantly demonstrated that 
the loss of homeostatic endocannabinoid (eCB) signaling of epidermal keratinocytes 
dramatically enhanced cutaneous inflammatory processes (4). In line with these 
findings, the CNR1 receptor antagonist/inverse agonist falcarinol triggered the 
expression of the pro-inflammatory interleukin (IL)-8 and chemokine (C-C motif) ligand 2 
(CCL2; also known as monocyte chemotactic protein 1, [MCP1]) in cultured human 
HaCaT keratinocytes in a CNR1 receptor-dependent manner (s7). Further, one of the 
key eCBs (i.e. anandamide; AEA) exhibited anti-allergic/anti-inflammatory effects in 
human skin, which could be abolished by CNR1 receptor inverse agonists falcarinol and 
rimonabant. These data, together with recent findings that activation of CNR1 in 
epidermal keratinocytes attenuated FITC-induced “atopic-like” dermatitis in a mouse 
model (s8), and that it limited the secretion of pro-inflammatory chemokines regulating T 
cell-dependent inflammation in the effector phase of contact hypersensitivity (s9), 
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strongly argue for that the ECS, and particularly the cutaneous eCB tone, plays a “gate-
keeper” role in the initiation phase of skin inflammation. 
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Supplementary experimental design 
 
Materials 
AM251 and AM630 were purchased from Cayman Chemical Company (Ann Arbor, MI, 
USA); URB597, γ-irradiated lipopolysaccharides from Escherichia coli 026:B6 (LPS) and 
lipoteichoic acid from Staphylococcus aureus (LTA) were obtained from Sigma-Aldrich 
(St. Louis, MO, USA). Tacrolimus (Protopic®) was purchased from Astellas Pharma US, 
Inc. (Northbrook, IL, USA), whereas WOBE440 and WOBE479 were provided by Dr. 
August Wolff GmbH & Co. KG Arzneimittel (Bielefeld, Germany). AM251 was dissolved 
in absolute ethanol (Sigma-Aldrich), while the solvent for AM630, URB597, WOBE440 
and WOBE479 was dimethyl sulphoxide (DMSO; Sigma-Aldrich). LPS and LTA were 
dissolved in filtered distilled water. In the case of the animal experiments, WOBE440 
and WOBE479 were dissolved in the 4:1 mixture of acetone and olive oil. Tacrolimus 
was applied in a formulation of mineral oil, paraffin, propylene carbonate, white 
petrolatum and white wax. 
Where applicable, in case of our in vitro experiments, AM251 and AM630 were applied 
20 minutes in advance, whereas the FAAH-inhibitors (URB597, WOBE440 and 
WOBE479) and the LTA were administered simultaneously. 
 
Cell culturing 
Human immortalized keratinocytes (HPV-KER; 7,8), as well as primary normal human 
epidermal keratinocytes (NHEKs) were cultured in serum-free EpiLife medium (Life 
Technologies Hungary Ltd., Budapest, Hungary) supplemented with Human 
Keratinocyte Growth Supplement (HKGS; in 1:100; Life Technologies Hungary Ltd.), 
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antibiotics (preformed mixture of penicillin and streptomycin in 1:100; PAA Laboratories 
GmbH., Pasching, Austria) and Fungizone® Antimicotic (in 1:200; Life Technologies 
Hungary Ltd.). 
 
Human skin samples were obtained after obtaining written informed consent from 
healthy individuals undergoing dermatosurgery, adhering to Helsinki guidelines, and 
after obtaining Institutional Research Ethics Committee’s and Government Office for 
Hajdú-Bihar County’s permission (protocol No.: DE OEC RKEB/IKEB 3724-2012; 
document No.: IX-R-052/01396-2/2012). NHEKs were isolated after overnight dermo–
epidermal separation in 2.4 IU/ml dispase (Roche Diagnostics, Berlin, Germany) by 
short trypsin (0.05%, Sigma-Aldrich) digestion. Cells were cultivated at 37°C in 
humidified, 5% CO2 containing atmosphere, the medium was changed every other day, 
and cells were sub-cultured at 70-80% confluence in both cases. 
 
Determination of cellular viability 
The viability of the cells was determined by measuring the conversion of the tetrazolium 
salt MTT (Sigma-Aldrich) to formazan by mitochondrial dehydrogenases. Cells were 
plated in 96-well plates (20,000 cells/well) in quadruplicates, and were cultured for 8, 24 
or 72 hours. Cells were then incubated with 0.5 mg/ml MTT for 2 hrs, and concentration 
of formazan crystals (as an indicator of number of viable cells) was determined 
colorimetrically as described previously (s10-11). Results were expressed as percentage 
of vehicle controls regarded as 100%. When applicable, curve fitting was performed by 
Origin Pro Plus 6.0 software (Microcal, Northampton, MA, USA) using “Exponential 
Decay 1” curve fitting option. 
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RNA isolation, reverse transcription, quantitative “real-time” PCR (Q-PCR) 
Q-PCR was performed as described previously (s11). Briefly, measurements were run 
on an ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA, 
USA) or Stratagene Mx3005P QPCR System (Agilent Technologies, Santa Clara, CA, 
USA) using the 5’ nuclease assay. Total RNA was isolated using TRIzol (Life 
Technologies Hungary Ltd., Budapest, Hungary), DNase treatment was performed 
according to the manufacturer’s protocol, and then 1 µg of total RNA were reverse-
transcribed into cDNA by using High Capacity cDNA Kit from Life Technologies Hungary 
Ltd.. PCR amplification was performed by using TaqMan primers and probes (assay ID-
s: Hs00155015_m1 for FAAH, Hs00174092_m1 for IL1A, Hs00174097_m1 for IL1B, 
Hs00985639_m1 for IL6 and Hs00174103_m1 for IL8) and the TaqMan universal PCR 
master mix protocol (Applied Biosystems). As internal controls, transcripts of 
peptidylprolyl isomerase A (cyclophilin A; PPIA) were determined (assay ID: Hs 
99999904_m1). The amount of the transcripts was normalized to those of the 
housekeeping gene using the ∆CT method. When indicated, the results were then 
normalized to the expression of the vehicle control (∆∆CT method). 
 
Western blotting 
Cells were harvested in lysis buffer (20 mM Tris-HCl, pH 7.4, 5 mM EGTA, 1 mM 4-(2-
aminoethyl) benzensulfonyl fluoride, protease inhibitor cocktail diluted 1:100, (all from 
Sigma-Aldrich) and the protein content was measured by a modified BCA protein assay 
(Pierce, Rockford, IL, USA). The samples were then subjected to sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis. 10% Mini Protean TGX gels (Bio-Rad, 
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Hercules, CA, USA) were loaded with equal (28 µg) amount of protein per lane. 
Samples were then transferred to nitrocellulose membranes, by using Trans-Blot® 
Turbo™ Nitrocellulose Transfer Packs and Trans-Blot Turbo™ System (both from Bio-
Rad), and then probed with rabbit-anti-human FAAH specific primary antibodies (Novus 
Biologicals, LLC, Littleton, Co, USA; in 1:250 dilution in 5% milk containing PBS). As 
secondary antibody, horseradish peroxidase-conjugated rabbit IgG Fc segment-specific 
antibodies (developed in goat, 1:1000 in 5% milk containing PBS, Bio-Rad) were used, 
and the immunoreactive bands were visualized by a SuperSignal® West Pico 
Chemiluminescent Substrate enhanced chemiluminescence kit (Pierce) using a KODAK 
Gel Logic 1500 Imaging System (Eastman Kodak Company, Kodak, Tokyo, Japan). To 
assess equal loading, membranes were re-probed with rabbit-anti-β-tubulin (TUBB) 
antibodies (1:1000, Novus Biologicals, LLC) and visualized as described above. 
Semiquantitative densitometric analysis of the signals was performed by using KODAK 
Molecular Imaging Software (Eastman Kodak Company, Rochester, NY, USA) or by 
using Image J software (National Institutes of Health, Bethesda, MD, USA). 
 
Determination of the FAAH-activity 
[ethanolamine-1-3H]-AEA (60 Ci/mmol) was purchased from American Radiolabeled 
Chemicals Inc. (St. Louis, MO, USA). Anandamide and (3-aminocarbonyl)[1,1-biphenyl]-
3-yl)-cyclohexylcarbamate (URB597) were purchased from Cayman Chemicals Europe. 
TrisHCl and EDTA were ordered from Sigma-Aldrich (Switzerland). Ultima Gold liquid 
scintillation cocktail was purchased from Perkin Elmer (Switzerland). 
The enzymatic activity of FAAH in NHEK and HPV-KER cell homogenates was 
assessed by determination of the hydrolysis of [ethanolamine-1-3H]AEA as previously 
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described (s12-16). NHEK and HPV-KER homogenates (100 µg per sample) were 
incubated for 15 min at 37°C in 10 mM TrisHCl, 1 mM EDTA (pH 9) with 5 µl vehicle 
(DMSO) or URB597 (final concentration: 100 nM) in a total volume of 500 µl. AEA was 
added as substrate using 5 µl of a mixture of [3H]AEA (0.5 nM) plus unlabeled AEA (final 
concentration: 10 µM). The reaction was stopped after 10 min by addition of 1 ml ice-
cold CHCl3:MeOH (1:1) and vigorous vortexing. The aqueous phase was collected after 
phase separation by centrifugation at 10,000 g at 4°C for 10 min. The radioactivity of 
produced [3H-ethanolamine] was measured by liquid scintillation counting on a Tri-Carb 
2100 TR liquid scintillation analyzer after addition of 3.5 ml Ultima Gold scintillation 
cocktail (PerkinElmer Life Sciences). The background was determined using buffer 
alone without homogenate and subtracted from all samples. Data are reported as mean 
values of n ≥ 3 independent experiments each of them performed in triplicates. 
 
Determination of apoptosis 
A decrease in the mitochondrial membrane potential is one of the earliest markers of 
apoptosis. Therefore, to assess the process, mitochondrial membrane potential of HPV-
KERs was determined using a MitoProbe™ DiIC1(5) Assay Kit (Life Technologies 
Hungary Ltd.). Cells (20,000 cells/well) were cultured in 96-well black-well/clear-bottom 
plates (Greiner Bio One, Frickenhausen, Germany) in quadruplicates and were treated 
with various compounds for 8-24 hrs. After removal of supernatants, cells were 
incubated for 30 minutes with DilC1(5) working solution (50 µl/well), then washed with 
PBS, and the fluorescence of DilC1(5) was measured at 630 nm excitation and 670 nm 
emission wavelengths using the FlexStation384 II or FlexStation 3 FLuorescence Image 
MicroPlate Readers (FLIPRs; Molecular Devices, San Francisco, CA). Relative 
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fluorescence values were expressed as percentage of vehicle controls regarded as 
100%. 
 
Determination of necrosis 
Necrotic processes were determined by SYTOX Green staining (Life Technologies 
Hungary Ltd.). The dye is able to penetrate (and then bind to the nucleic acids) only to 
necrotic cells with ruptured plasma membranes, whereas healthy cells with intact 
surface membranes sh w negligible SYTOX Green staining. Cells were cultured in 96-
well black-well/clear-bottom plates (Greiner Bio One), and treated with various 
compounds for 8-24 hrs. Supernatants were then discarded, and the cells were 
incubated for 30 minutes with 1 µM SYTOX Green dye. Following incubation, cells were 
washed with PBS, the culture medium was replaced, and fluorescence of SYTOX Green 
was measured at 490 nm excitation and 520 nm emission wavelengths using FLIPR 
(Molecular Devices). DilC1(5) and SYTOX Green labeling were performed as co-labeling 
of the same samples. 
 
Experiments on NC/Tnd mice 
The study was conducted at BioTox Sciences (BTS; San Diego, CA, USA). The study 
design and animal usage were reviewed and approved by the Institutional Animal Care 
and Use Committee (IACUC; No. 1109-05) for compliance with regulations prior to study 
initiation. Animal welfare was in compliance with the Guide for the Care and Use of 
Laboratory Animals and BioTox Sciences SOPs. All experiments on the animals were 
designed and performed by adopting the principles of “Guide for the Care and Use of 
Laboratory Animals, 8th Edition. National Academy Press, Washington, DC, 2010”. 
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8–9 weeks old male NC/Tnd mice (previously often referred to as NC/Nga; 9) were 
involved into the study. Mice were exposed to dust mite antigen as necessary to initiate 
the development of the disease condition. A standardized mixture of dust mite extracts 
(15,000 AU/ml of Dermatophagoides pteronyssinus and D. farinae) was used (Hollister-
Stier Laboratories, Spokane, WA, USA). Animals were randomized on the basis of the 
average total clinical disease score for each group (approximately 1), and then treated 
for 30 days with vehicle (4:1 mixture of acetone:olive oil) or test substances. Clinical 
score was determined from observations of the upper back/lower neck (i.e., the area that 
received topical treatment) with a scale of 0–3 (0: absent; 1: mild; 2: moderate; 3: 
severe) for erythema, edema or papulations, and for oozing, crusts or hemorrhages. 
Each mouse received a single daily topical dose that was applied to the upper 
back/lower neck area. The study was run in two equal halves, each starting with N=4–5 
animals. Evaluation of total disease score and measurement of ear thickness was 
performed as indicated (twice a week). 
 
Determination of cytokine release (ELISA) 
Cells were treated as indicated for 24 hours. Supernatants were collected, and the 
released amount of IL6, and IL8 was determined using OptEIA kits (BD Pharmingen, 
Franklin Lakes, NJ, USA) according to the manufacturer’s protocol. 
 
Statistical analysis 
Data were analyzed and graphs were plotted by using Origin Pro Plus 6.0 software 
(Microcal, Northampton, MA, USA), using Student’s two-tailed two samples t-test and 
P<0.05 values were regarded as significant differences.  
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Supplementary Conclusion section 1 
The human skin establishes a complex homeostatic barrier (i.e. physico-chemical, 
immunological, microbiological) which protects the body against physical, chemical or 
microbiological challenges (s22-24). The physico-chemical barrier functions are 
dependent on the precisely orchestrated co-ordination of various cutaneous functions, 
such as e.g. proliferation and differentiation of the epidermal keratinocytes, sebum 
production, etc. (s22-24). In addition, the organization of the immunological barrier is 
based on complex, multi-directional interactions between the cutaneous commensal 
microbiome and various skin cells (s1-6, s25-27). Indeed, dysregulation of the 
immunological barrier, leading to several inflammation-accompanied cutaneous 
diseases such as e.g. atopic dermatitis (AD), show extremely high (and ever increasing) 
prevalence in the industrial countries (s26). 
For chronic cutaneous inflammatory diseases, there is still a need for the development 
of novel, efficient and safe topical drugs with an improved benefit-risk profile as 
compared to topical corticosteroids or calcineurin inhibitors. It is widely accepted that in 
cutaneous inflammatory diseases (e.g. in AD), dysregulation of the local, cutaneous 
immune system impairs the physico-chemical skin barrier, thereby greatly contributing to 
the progression of the disease and the worsening of the symptoms (s27-28). 
Although epidermal expression of FAAH was described long ago (s29), our data are the 
first ones arguing for that this enzyme, via decreasing the anti-inflammatory eCB tone 
(and on the other hand, subsequently increasing concentration of the pro-inflammatory 
“AEA degradation product” AA) shifts the AEA/AA steady-state towards a pro-
inflammatory direction (Supplementary Figure 7a-b). 
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We found that activity (but not mRNA expression) of FAAH was strongly up-regulated 
upon TLR2-activation indicating that TLR2-coupled signaling plays a key role in the post-
transcriptional regulation of FAAH (Supplementary Figure S2; Figure 1a-f). 
Furthermore, we also showed that inhibition of FAAH led to significant anti-inflammatory 
actions (Figure 2a-d) via the indirect (5,6) activation of CNR1 and CNR2 
(Supplementary Figure S3). Moreover, we could also demonstrate that FAAH-inhibitors 
significantly ameliorated the cutaneous symptoms and reduced ear thickness of NC/Tnd 
mice, with an efficiency comparable to tacrolimus (Figure 2e-f; Supplementary Figure 
S6a-d), without any obvious macroscopic or behavioral side-effects in the course of the 
one month long treatment period. Thus, FAAH might provide an important (and 
previously un-described) contribution to the cutaneous inflammatory responses. These 
data invite further, extensive studies to unveil whether disturbed FAAH expression 
pattern and activity might indeed play a role in the pathogenesis of inflammation-
accompanied skin diseases. Considering all these intriguing findings, inhibition (and 
thereby normalization) of TLR2-activation-induced epidermal FAAH-activity appears to 
be a highly targeted approach in restricting cutaneous inflammation. 
 
Supplementary Conclusion section 2 
Epidermal keratinocytes, via the controlled release of pro-inflammatory cytokines, are 
key players in the recruitment and activation of “professional” immune cells (s25); the 
regulation of their immunological activities is a crucial check-point of the initiation and 
orchestration of cutaneous inflammatory processes leading to the clinical signs of 
dermatitis. However, besides the expected keratinocyte-specific beneficial effects of the 
topically applied FAAH-inhibitors, one should also take into consideration the putative 
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effects of the elevated eCB-tone on the “professional” cutaneous immune cells. Indeed, 
elevation of the epidermal eCB tone, besides acting directly on the epidermal 
keratinocytes, may exert further anti-inflammatory actions by affecting epidermal 
Langerhans cells and sensory neurons (3), thereby contributing to the anti-inflammatory 
actions demonstrated in the in vitro part of our current study. Last, but not least, it is also 
noteworthy that topical administration of such inhibitors could also minimize the risk of 
systemic side-effects, holding out the promise of the development of novel, highly 
targeted, efficient, yet safe therapeutic tools. 
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Supplementary Figures 
 
 
Supplementary Figure S1 Chemical structures of the novel FAAH-inhibitors WOBE440 
and WOBE479 (6) 
  
(a)
(b)
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Supplementary Figure S2 FAAH is expressed in HPV-KERs at the mRNA level 
FAAH mRNA expression of HPV-KERs following LPS, LTA (5 and 10 µg/ml, 
respectively) or vehicle treatments (1, 3, 6, 12 and 24 hrs). Data are presented by using 
the ∆∆CT method regarding peptidylprolyl isomerase A (PPIA)-normalized mRNA 
expression of the 1-hr control as 1 (solid line). Data are expressed as mean±SD of three 
independent determinations. One additional experiment yielded similar results. 
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Supplementary Figure S3 FAAH-inhibitors exert remarkable anti-inflammatory actions 
via activating CNR1 and CNR2 receptors 
Q-PCR analyses of HPV-KERs following the indicated 24-hr treatments (AM251: 1 µM; 
AM630: 1 µM; LTA: 10 µg/ml; WOBE440: 100 nM; WOBE479: 200 nM). Data are 
presented by using ∆∆CT method regarding PPIA-normalized mRNA expressions of the 
vehicle control as 1 (solid line). Data are expressed as mean±SD of 3 independent 
determinations. One additional experiment yielded similar results. ***P<0.001; n.s.: non-
significant difference. 
  
 
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
(e
x
p
re
s
s
io
n
 o
f 
v
e
h
ic
le
 c
o
n
tr
o
l =
 1
)
3
1
2
6
5
4
0
URB597
+LTA
***
***
WOBE440
+LTA
WOBE479
+LTA
***
LTA
LTA alone
LTA + FAAH-inhibitor
LTA + FAAH-inhibitor + AM251 + AM630
IL1A expression
 
 
 
 
LTA + AM251 + AM630
n.s.
Page 32 of 40
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
16 
 
 
Supplementary Figure S4 Effective anti-inflammatory concentrations of the FAAH-
inhibitors are not cytotoxic 
(a, c) MTT-assays. Viability of HPV-KERs following 8- (a) or 24-hr (c) treatments. (b, d) 
Cell death (DilC1(5)-SYTOX Green double labeling of HPV-KERs) assays following 8- 
(b) or 24-hr (d) treatments. (a-d) Results are expressed in the percentage of the vehicle 
control (100%, solid line) as mean±SEM of four independent determinations. One 
additional experiment yielded similar results. 
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Supplementary Figure S5 Effective anti-inflammatory concentrations of the novel 
FAAH-inhibitors are not cytotoxic even in case of long-term application 
(a-b) MTT-assays. Viability of HPV-KERs following 72-hr treatments. Results are 
expressed in the percentage of th  vehicle control (100%, solid line) as mean±SEM of 
four independent determinations. One additional experiment yielded similar results. 
Arrows indicate the effective anti-inflammatory concentrations of the compounds. TC50: 
the estimated half-cytotoxic concentration of the substances. 
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Supplementary Figure S6 Topically applied FAAH-inhibitors improve symptoms of 
NC/Tnd mice 
Representative images of the animals at the end of the study period (1 month). (a) 
control group. (b) tacrolimus group. (c) WOBE440 group. (d) WOBE479 group. 
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Supplementary Figure S7 Overview of the role of FAAH in mediating cutaneous 
inflammation 
The inflammation-controlling “eCB steady-state” (a) and mechanism of the anti-
inflammatory action of FAAH-inhibitors (b). Color codes: TLR2-activation mediated 
actions; effects of FAAH-inhibition; result of FAAH-activity. 
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